“Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients With Locally Advanced Cutaneous Squamous Cell Carcinoma”. 2018. SKIN The Journal of Cutaneous Medicine 2 (December): S77. https://doi.org/10.25251/skin.2.supp.77.